7707 Fannin Street
Suite 200
Houston, TX 77054
United States
832 968 4888
https://kiromic.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 35
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Brian Hungerford CPA, CGMA | Chief Financial Officer | 160.69k | N/A | 1976 |
Dr. Leonardo Mirandola Ph.D. | Chief Scientific Officer & Interim COO | 383.32k | N/A | 1982 |
Dr. Scott Dahlbeck M.D., Pharm.D., PharmD | Chief of Staff | 359.08k | N/A | 1962 |
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
Kiromic BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.